Flawed PI and CMI for Thyroid and Adrenal Medications: Where to From Here?

E-ISSN： 2055-2335|37|2|88-89

ISSN： 1445-937x

Source： JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol.37, Iss.2, 2007-06, pp. : 88-89

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Acetaminophen safety and hepatotoxicity – where do we go from here?

By Amar Patrick J Schiff Eugene R

Expert Opinion on Drug Safety, Vol. 6, Iss. 4, 2007-07 ,pp. : 341-355

Informa Healthcare

Access to resources Recommend Favorite

Where Do We Go from Here? The Importance of Initial Values

By Mehta M.A.

Neuropsychopharmacology, Vol. 27, Iss. 5, 2002-11 ,pp. : 879-880

Elsevier

Access to resources Recommend Favorite

Tamoxifen for breast cancer prophylaxis: where to from here?

Inpharma, Vol. 1, Iss. 1219, 2000-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Assessing the Risks of Adverse Endocrine-Mediated Effects: Where to from Here?

By Ashby J. Odum J. Tinwell H. Lefevre P.A.

Regulatory Toxicology and Pharmacology, Vol. 26, Iss. 1, 1997-08 ,pp. : 80-93

Academic Press

Access to resources Recommend Favorite

Contingency Management for Smoking Cessation: Where Do We Go from Here?

Current Drug Abuse Reviews, Vol. 1, Iss. 3, 2008-11 ,pp. : 340-349

Bentham Science Publishers

Access to resources Recommend Favorite